Juliana Alvares-Teodoro

Professor of Pharmacy
Faculty of Pharmacy, Universidade Federal de Minas Gerais (UFMG)
Belo Horizonte, Minas Gerais, Brazil

Presentation(s):

• PB0227 - Cost evaluation of clotting factors concentrates before, during and after immune tolerance Induction according to outcome in Congenital Haemophilia A and inhibitor

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0550 - Cost-effectiveness of prophylaxis with emicizumab or bypass agents in children with severe hemophilia A and high-response inhibitors after immune tolerance failure: a Brazilian perspective

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0551 - Girl with mild inherited hemophilia A and high-responding inhibitor associated with Melnick-Needles osteodysplasty syndrome: a case report of emicizumab prophylaxis effectiveness

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0534 - Improved well-being in people with hemophilia A and inhibitor in emicizumab prophylaxis

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB1204 - Bleeds during the first year of emicizumab prophylaxis: preliminary results of the Brazilian Emicizumab Registry (EMCase Project)

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1237 - Functional Independence in People with Hemophilia A on Emicizumab Prophylaxis

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1205 - Joint health in people with hemophilia A and inhibitors during emicizumab prophylaxis (EMCase Study)

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1265 - Switching prophylaxis during an immune tolerance induction evolving with failure: a case report from a Brazilian Hemophilia Treatment Center

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT